Mark R. Bamforth, Director at PEREGRINE PHARMACEUTICALS INC (PPHM), bought 35,966 shares at $4.51 ($162K) on 2017-10-27, disclosed to the SEC on 2017-10-27.
Open-market purchase of $162k PPHM by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Nothing distinguishes this filing.
| Filing → |
| CDMO | BUY | 2020-03-16 | $104K | — | Filing → |
| CDMO | BUY | 2018-02-20 | $113K | — | Filing → |
| PPHM | BUY | 2017-10-27 | $444K | — | Filing → |